Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone

ROVI Granting of partially reimbursable aid co-financed by the European Regional Development Fund (ERDF) 1 For more information: Consuelo Trillo Díaz [email protected] Tel: + 34 91 244 44 10 GRANTING OF PARTIALLY REFUNDABLE AID FOR THE DEVELOPMENT OF A NEW QUARTERLY FORMULATION OF RISPERIDONE Madrid - September 15th, 2020. Last June, Rovi signed a financing agreement with the Center for Industrial Technological Development (CDTI) to support its Research and Development work, by granting partially reimbursable aid co -financed by the European Regional Development Fund (ERDF). ) through the M ulti-regional Operational Program for Smart Growth. This program is included in the framework of the investment objective in growth and employment, in its Priority Axis 01 (Promoting research, technological development and innovation) and Specific Objectiv e 1.1.2 (Strengthening of R&D institutions and creation , consolidation and improvement of scientific and technological infrastructures). The funding received is intended to develop R&D&i activities within the framework of the project “Development of a new quarterly formulation of Risperidone”, with file number IDI- 20200346. ROVI is a company committed to innovation, with a portfolio composed of more than 500 patents, of which 408 have been granted and 96 are in examination and evaluation pha se. ROVI has a wide portfolio of products in the research and development phase, mainly focused on three technological areas: glycomics, multilayer systems for application to urethral catheters and drug delivery technologies (ISM ®). ISM® technology is the exclusive property of ROVI and is internationally patented until 2033. ISM® has been designed by ROVI to overcome most of the drawbacks of prolonged release oral or parenteral formulations, and, consequently, it presents significant techn ical advantages such as its versatility in administration, its high encapsulation efficacy of the active ingredient, the stability of the biodegradable matrix formed, or a greater control in the initial release of the drug, offering clinically significant release profiles from the first day, among others. This new project aimed at developing a quarterly formulation of Risperidone is framed within this area where the company is already in the final stages of development of the first candidate. ROVI Granting of partially reimbursable aid co-financed by the European Regional Development Fund (ERDF) 2 ABOUT ROVI is a pan -European pharmaceutical company, specialized and dedicated to the research, development, manufacturing under license and commercialization of small molecules and biological specialties. The company, in a continuous process of international expansion, has subs idiaries in Portugal, Germany, United Kingdom, Italy, France and Poland, and has a diversified portfolio of more than 40 commercialized products, in which its reference product, Bemiparin, stands out. which is already marketed in 56 countries world wide. Likewise, in 2017, ROVI started the commercialization of its internally developed biosimilar enoxaparin in Europe. ROVI continues to develop the ISM® Platform technology, a leading line of research in the field of prolonged release of drugs with proven advantages. For more information visit www.rovi.es.

The release as fetched from its publisher. rovi.es ↗